TelixAI^TM seeks to increase the efficiency and reproducibility of clinicians' imaging assessments using advanced analysis capabilities with an initial focus on prostate cancer. The platform is designed to do this by automatically separating healthy versus abnormal tracer uptake and then classifies lesions as either visceral (soft tissue) or bone lesions.

Invicro has a depth of experience in AI, machine learning and algorithm development for medical imaging. Its industry leading medical image analyst team consists of over fifty medical image processing scientists. The commercial objective of the development partnership is the submission to the United States Food and Drug Administration (FDA) 510(K) approval for software as a medical device.

A demonstration of TelixAI^TM  was presented this week at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting being held in Vancouver, BC from June 11-14.

Telix Chief Scientist, Dr. Michael Wheatcroft said, "We are pleased to be advancing the TelixAI^TM platform with Invicro, which aims to further enhance the utility of molecular imaging starting with Illuccix. Our investment in TelixAI^TM is expected to extend into multiple applications for Telix's late-stage imaging assets, including TLX250-CDx, which is currently completing a Phase III pivotal trial in renal cancer imaging."

CEO of Invicro, Matt Silva, Ph.D., continued, "Invicro is delighted to bring our deep expertise in PET imaging, AI and machine learning and take this collaboration with Telix's Research and Innovation team into the next stage. We are excited about the possibility of bringing this software to realization with Illuccix and for the potential impact on clinicians' decision-making and patient outcomes with Telix's broad theranostic pipeline."